On February 22, 2022, the company received the Notification of Approval of Supplementary Application for Drugs with the name of "enalapril maleate tablets" (specification: 10mg) approved and issued by the State Drug Administration, indicating that the drug passed the consistency evaluation of generic drug quality and efficacy, which is the first product approved by the company for consistency evaluation. "Enalapril maleate tablet" is mainly used for the treatment of hypertension and heart failure. It is an angiotensin converting enzyme inhibitor widely used in the domestic market at present. The approval of this drug consistency evaluation is the result of the joint efforts of the company's R&D department and production department. I believe that with this successful experience, more varieties will pass the consistency evaluation, which lays a good foundation for the rapid improvement of the company's performance.

In the afternoon of March 24, Li Baozhen, director of the Standing Committee of Kaiping Municipal People's Congress, led a team to visit our company to carry out research work, deeply understand the enterprise development plan and listen to the demands of enterprises. Feng Wuzhan, Secretary of the Party Committee of Yueshan Town, and Lu Cai'e, Chairman of the People's Congress of Yueshan Town, were accompanied.

In the afternoon of March 24, Li Baozhen, director of the Standing Committee of Kaiping Municipal People's Congress, led a team to visit our company to carry out research work, deeply understand the enterprise development plan and listen to the demands of enterprises. Feng Wuzhan, Secretary of the Party Committee of Yueshan Town, and Lu Cai'e, Chairman of the People's Congress of Yueshan Town, were accompanied.

In order to gain an in-depth understanding of the stock of epidemic prevention and control materials in Kaiping City and help enterprises to solve difficulties, a delegation led by the Secretary and Director of the Party Group of Kaiping Municipal Market Supervision and Administration Bureau, Lao Haiming, and the member of the Party Group, Liang Junquan, visited the company for research and guidance on the afternoon of April 8, 2022. Yin Jinxi, the executive deputy general manager of the company, and Luo Yongchi, the deputy general manager of the company received warmly. At the meeting, Director Lao Haiming and his party first learned about the current production situation of the company's mask workshop, and Mr. Yin and Mr. Luo made a detailed introduction one by one. The research team strongly affirmed the company's practice of fully supporting and cooperating with the relevant work of Kaiping Development and Reform Bureau, and making every effort to firmly build the security line of epidemic prevention and control materials in our city. Subsequently, Director Lao inquired about the difficulties and assistance the company encountered in the development process. General Manager Yin and General Manager Luo, in combination with the actual situation of the company, reflected to the research team in detail some of the difficulties faced by the company in the procurement of raw materials. The research team attached great importance to this and said that it would actively coordinate and guide the company to solve relevant problems, and encourage the company to continue to maintain firm confidence and good development momentum, and continue to make contributions to the economic and social development of Kaiping.

On the morning of April 19, Li Wencong, a member of the Party Leadership Group and Vice Chairman of the Jiangmen Municipal Committee of the Chinese People's Political Consultative Conference, led a team to visit our company to carry out research, deeply understand the development of the enterprise, and warmly discussed the topic of the pharmaceutical industry chain. Yin Jinxi, the executive vice general manager of the company, gave a warm reception. The research meeting was conducted in the form of a symposium. At the meeting, Mr. Yin briefed the research team on the company's history, production and operation and development plan. After listening to the report, Chairman Li fully affirmed the company's development performance and important contributions to the local economic development, and also asked about the difficulties faced by the company's current development, for which President Yin expressed his gratitude. The two sides had in-depth exchanges with the research team on industrial integration and supply chain integrity of pharmaceutical enterprises. General Yin believed that, with the aging of the population and the improvement of health awareness in China, the biomedical association is a rising and prosperous industry, and will play an increasingly important role in national production. He introduced the current situation of industrial clusters in Shandong, Zhejiang, Jiangsu and other powerful pharmaceutical provinces to Chairman Li, and proposed that Guangdong Province and Jiangmen City could learn from and draw on their industrial development ideas, and train pharmaceutical majors in colleges and universities The government has put forward a series of suggestions on introducing excellent talents, vigorously attracting investment from key chemical and biological enterprises in other provinces, and the layout of bio-pharmaceutical industrial parks. The research team expressed its gratitude for the company's contributions and suggestions, said that it would have the opportunity to further discuss this in the future, and also encouraged the company to further explore its own advantages, improve its own industrial chain, continuously increase its strength, and make greater contributions to the city's great health cause.

In order to deeply understand the recruitment needs of employers and further strengthen the exchange and cooperation with employers in talent training, internship base construction, employment recommendation, scientific research cooperation and other aspects, Kuang Weihong, member of the Standing Committee of the Party Committee and Vice President of Guangdong Medical University, led the relevant leaders of the Human Resources Department and the School of Pharmacy of Guangdong Medical University to the company for cooperation and exchange in the morning of April 25. Yin Jinxi, the executive deputy general manager of the company, and Luo Yongchi, the deputy general manager of the company received warmly. At the exchange symposium, President Kuang introduced the general situation of Guangdong Medical University, focusing on the main measures and achievements of the university in school-enterprise cooperation, talent training, employment and entrepreneurship of graduates in recent years. President Kuang said that as an "old friend" of Peter, the school highly recognized that the company provided students with a professional and promising internship and employment platform and excellent teaching ability. General Manager Luo said that Guangdong Medical University has high-level teaching facilities and distinctive school-running characteristics, and there is a lot of room for future cooperation between the two sides. In combination with the actual situation of the company and the current human resources planning, this paper puts forward the views on the demand for talents from the aspects of drug production process, quality management, product research and development, etc.